US FDA Resumes China, India Inspections In Bid To Keep Drug Approvals On Schedule

The US Food and Drug Administration has resumed inspections in China and plans to in India soon as the agency struggles to meet user fee goals during the pandemic, according to Patrizia Cavazzoni, acting director of the Center for Drug Evaluation and Research.

“It has required extensive efforts for FDA to meet user fee goals during the COVID-19 pandemic at a level similar to other years,” Cavazzoni stated in a 26 January Twitter post